Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julia Glaser

Vascular Surgery Philadelphia, PA Medical Doctor

NPI 1912346784 CMS profile 987235

3400 Spruce St, Philadelphia, PA 19104

Open in the dashboard

General payments

$16,975

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julia Glaser of Philadelphia, PA is reported in the CMS Open Payments database as having received $16,975 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,250 16
2024 General $922 12
2023 General $1,753 12
2022 General $6,715 18
2021 General $14 1
2020 General $563 9
2019 General $2,756 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julia Glaser
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Julia Glaser were reported at $4,250. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Julia Glaser Vascular Surgery median Middle half National median
2019 $2,756 $796 $226–$2,363 $163
2020 $563 $348 $118–$1,110 $114
2021 $14 $471 $158–$1,421 $132
2022 $6,715 $725 $222–$2,183 $149
2023 $1,753 $836 $257–$2,440 $160
2024 $922 $909 $252–$2,619 $164
2025 $4,250 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,253 10 payments
  2. Endologix, Inc. $3,835 36 payments
  3. Novartis Pharmaceuticals Corporation $3,215 3 payments
  4. Bolton Medical Inc $2,597 8 payments
  5. W. L. Gore & Associates, Inc. $1,507 11 payments
  6. Silk Road Medical, Inc. $356 4 payments
  7. Veryan Medical Incorporated $270 1 payment
  8. Smith+Nephew, Inc. $188 4 payments
  9. Baxter Healthcare $156 3 payments
  10. Maquet Cardiovascular U.S. Sales, L.L.C. $142 3 payments
  11. Other $457 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,631 82 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,600 1 payment
  3. Consulting Fee $3,100 1 payment
  4. Education $2,442 6 payments
  5. Travel and Lodging $2,202 6 payments
Products named General payments · program years 2019–2025
  1. AngioJet Ultra 5000A $3,717 2 payments
  2. Grafts $2,231 4 payments
  3. Ovation $1,306 17 payments
  4. ENDOCROSS Device $1,079 7 payments
  5. Torus Stent Graft System $1,079 7 payments
  6. GORE VIABAHN VBX Balloon Expandable Endo $1,065 6 payments
  7. AFX $607 15 payments
  8. Alto Abdominal Stent Graft System $523 4 payments
  9. Vascular Graft $442 5 payments
  10. ENROUTE Transcarotid Neuroprotection System $356 4 payments
  11. Other $3,406 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$85,074

Medicare's payments for the services billed

Medicare patients

492

Average age 74

Services billed

922

247 women, 245 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Arthritis 53%
Chronic kidney disease 48%
Diabetes 47%
Heart failure 42%
Atrial fibrillation 33%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $45
$45 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record